HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.

Abstract
Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in various human cancers and has been used as a therapeutic target for tumors. This study screened natural products to identify compounds that inhibit STAT3 activity using a STAT3-dependent luciferase reporter system. Sugiol was identified as a compound that decreased luciferase activity in a dose-dependent manner. Sugiol specifically inhibited STAT3 phosphorylation at Tyr-705 in DU145 prostate cells, and this inhibition was independent of the STAT3 upstream kinase. Sugiol induced cell cycle arrest and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin. Notably, we observed that sugiol interacted with transketolase, an enzyme in central metabolism, and increased ROS levels leading to the activation of ERK, which inhibits STAT3 activity. The protein phosphatase MEG2 was also responsible for sugiol-induced STAT3 dephosphorylation. The inhibitory effect of sugiol on cell growth was confirmed using the DU145 mouse xenograft model. We propose that sugiol inhibits STAT3 activity through a mechanism that involves the inhibition of transketolase, which leads to increased ROS levels and MEG2 activation in DU145 cells. Therefore, sugiol is the first compound regulating STAT3 activity via modulation of cancer metabolic pathway and we suggest the use of sugiol as an inhibitor of the STAT3 pathway for the treatment of human solid tumors with activated STAT3.
AuthorsSeung-Nam Jung, Dae-Seop Shin, Hye-Nan Kim, Yoon Jung Jeon, Jieun Yun, Yu-Jin Lee, Jong Soon Kang, Dong Cho Han, Byoung-Mog Kwon
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 97 Issue 1 Pg. 38-50 (Sep 01 2015) ISSN: 1873-2968 [Electronic] England
PMID26212545 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Diterpenes
  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Reactive Oxygen Species
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • sugiol
  • Transketolase
  • PTPN9 protein, human
  • Protein Tyrosine Phosphatases, Non-Receptor
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (pharmacology, therapeutic use)
  • Carcinoma (drug therapy, enzymology, metabolism)
  • Cell Line, Tumor
  • Diterpenes (pharmacology, therapeutic use)
  • Enzyme Activation (drug effects)
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Female
  • Genes, Reporter (drug effects)
  • Humans
  • MAP Kinase Signaling System (drug effects)
  • Male
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Proteins (agonists, antagonists & inhibitors, genetics, metabolism)
  • Prostatic Neoplasms (drug therapy, enzymology, metabolism)
  • Protein Tyrosine Phosphatases, Non-Receptor (chemistry, metabolism)
  • Reactive Oxygen Species (agonists, metabolism)
  • STAT3 Transcription Factor (agonists, antagonists & inhibitors, genetics, metabolism)
  • Transketolase (antagonists & inhibitors, chemistry, metabolism)
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: